Profile
Linda R.
Judge worked as a Director of Intellectual Property at Cell Genesys, Inc. from 2001 to 2004.
She then worked as a Partner of Intellectual Property at DLA Piper LLP (United States) from 2004 to 2007.
After that, she worked as a Vice President of Intellectual Property at Talphera, Inc. Ms. Judge received graduate degrees from The California State University and Santa Clara University.
Former positions of Linda R. Judge
Companies | Position | End |
---|---|---|
DLA Piper LLP (United States)
DLA Piper LLP (United States) Miscellaneous Commercial ServicesCommercial Services DLA Piper LLP provides legal services to clients. It offers services in the areas of corporate and securities, venture capital and emerging companies, litigation. The company was founded in 2005 and it is headquartered in Baltimore, MD. | Corporate Officer/Principal | 2007-09-30 |
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Corporate Officer/Principal | 2004-07-31 |
TALPHERA, INC. | Corporate Officer/Principal | - |
Training of Linda R. Judge
Santa Clara University | Graduate Degree |
The California State University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
TALPHERA, INC. | Health Technology |
Private companies | 2 |
---|---|
Cell Genesys, Inc.
Cell Genesys, Inc. Pharmaceuticals: MajorHealth Technology Cell Genesys is a development-stage biotechnology firm focuses on gene-modification technologies to treat cancer. The company's lead product technology is its GVAX vaccine platform. Cell Genesys is working on GVAX vaccines for lung, prostate, and pancreatic cancer, as well as for leukemia and multiple myeloma, another blood cancer. Its oncolytic viral therapy platform uses specially engineered adenoviruses (such as the common cold) to kill cancer cells; the firm's lead candidate from this platform targets prostate cancer. | Health Technology |
DLA Piper LLP (United States)
DLA Piper LLP (United States) Miscellaneous Commercial ServicesCommercial Services DLA Piper LLP provides legal services to clients. It offers services in the areas of corporate and securities, venture capital and emerging companies, litigation. The company was founded in 2005 and it is headquartered in Baltimore, MD. | Commercial Services |
- Stock Market
- Insiders
- Linda R. Judge